Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkRates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients with Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

This retrospective cohort study included 2,833 patients with stage IB to IIIA NSCLC who enrolled in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study from August 18, 2014, to April 1, 2019. Although 93% received surgical resection, just 53% had adequate lymph node dissection and 57% received any adjuvant chemotherapy. The authors suggest more effort at optimizing use of proven therapies in this patient population.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form